Dow Reports Increase In Q4 Sales
Published: 04-Feb-2010
Dow has reported a net income from continuing operations of $178m for the fourth quarter of 2009, compared to the net loss from continuing operations of $1.55 billion in the fourth quarter of 2008.
Reported sales in the quarter increased 15% to $12.5 billion, compared to reported sales in the same period last year. EBITDA on a pro forma basis, excluding certain items, increased $809m versus the same quarter last year, with the combined performance segments up more than 85%.
Andrew Liveris, chairman and chief executive officer of Dow, said: "Dow delivered significantly better year-over-year revenue and earnings in the fourth quarter driven largely by volume gains across virtually all operating segments and improved equity earnings. Emerging geographies were a major factor in our results for the quarter, with volume up an impressive 33 %, truly reflecting the strength of our broad geographic footprint.
"Quarterly equity earnings returned to a level not seen since before the economic downturn, further demonstrating the strategic importance of our joint ventures. We achieved all of this while furthering our growth strategy and by maintaining our focus on financial discipline. This allowed us to grow revenues, volume, and earnings while increasing our R&D investments yet still achieving reductions in structural costs."
Dow also reported full-year earnings of $0.32 per share, or $0.63 per share excluding certain items and discontinued operations. Reported earnings for 2008 were $0.62 per share, or $1.79 per share excluding certain items and discontinued operations. The company has also reported sequential sales improvements throughout the year.
Mr. Liveris added: "We see demand in emerging geographies continuing to show sustained growth, which bodes well for global growth. Growth will continue to lag in the US and Europe, however, as high unemployment persists and questions about the sustainability of government stimulus spending remain. Dow’s ongoing financial discipline, transformed portfolio and strong presence in emerging geographies position us well to benefit from an economic recovery. Throughout 2009, this approach delivered sequential revenue growth which accelerated during the fourth quarter.
"This operating discipline has served us well last year, and will continue throughout 2010. This, coupled with our broad geographic footprint, larger portfolio of specialty businesses, invigorated innovation engine and world-class plastics franchise, will drive earnings growth into the future."
Network Sites

Suppliers To This Sector
Browse A-Z
Valsynthese
Hazardous Chemistry in Safe Hands ...
USB
Products from Affymetrix ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
Thomson Reuters
The World's Leading Source of Life Sciences Intelligent Information ...
TAPI
A Leading Global Supplier of Active Pharmaceutical Ingredients ...
Pharma IQ
Workshops, Conferences and Training Courses for Pharmaceutical Professionals ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully